美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

猴痘概念

2,133.91

+37.731.80%

涨家数：7

跌家数：3

平家数：1

市盈率：- -

高：2,135.98

开：2,097.09

低：2,089.87

收：2,096.18

成交量：1.14亿

成交额：22.39亿

市值：2,351.16亿

流通市值：2,343.93亿

数据加载中...

总览新闻资讯

AETHLON MEDICAL与NORTH IMMUNOLOGY达成合并协议后，股价飙升467%至8.16美元。

Aethlon Medical与North Immunology合并后股价飙升

Aethlon Medical宣布与North Immunology达成合并协议，盘前股价飙升87.4%至2.68美元

Aethlon Medical：合并前原股东持股约4.75%，North Immunology股东将掌控合并后公司约95.25%股权

Aethlon Medical合并案揭晓：North Immunology原股东预计持有合并实体约95.25%股份

Aethlon Medical与North Immunology合并，共推新型IL-13×IL-18双特异性抗体治疗特应性皮炎

吉利德科学扩大六项免许可费自愿授权协议，力推每年一次HIV预防药Lenacapavir

Viatris旗下Wakix®（Pitolisant）获日本批准，系发作性睡病及阻塞性睡眠呼吸暂停综合征相关日间过度嗜睡的首创疗法

吉利德科学携手巴西卫生部，共促Lenacapavir本地化生产新篇章

吉利德科学：持续探索与泛美卫生组织合作，助力各国准备好并扩大长效艾滋病预防措施的普及

吉利德科学携手泛美卫生组织，加速拉美及加勒比地区HIV预防药物Lenacapavir的可及性

吉利德高管表示，未来几个季度HIV市场增长或将回归2%-3%常态水平

吉利德高管透露：周服HIV预防药物有望2027年第一季度上市

Leerink基于增长势头改善，给予Viatris“跑赢大盘”评级

Assembly Biosciences有望获得高达2.8亿美元里程碑付款及美国境外特许权使用费

Assembly Biosciences旗下Gs-1179预计2026年底前将推进至生殖器疱疹二期临床试验阶段

Assembly Biosciences：吉利德独享HSV HPI项目临床开发与商业化权利

Assembly Biosciences行使与吉利德关于HSV解旋酶-引物酶抑制剂项目的美国利润分成选择权

吉利德科学(GILD)股票9月8日盘中下跌3.26%：释放什么信号？

TradingKey中文

第4次更新-鉴于市场供应存在担忧，美国食品药品监督管理局正与制造商合作，以增加雌激素贴片的供应量

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.etasphere.com/hans/stock/BK4583/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"猴痘概念","latestPrice":2133.9138,"timestamp":1789675199999,"preClose":2096.1792,"halted":0,"volume":114156601,"delay":0,"changeRate":0.018002,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":37.734619,"latestTime":"09-17 16:00:00 EDT","open":2097.0935,"high":2135.9778,"low":2089.8677,"amount":2238615371.45466,"amplitude":0.021997,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789738200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.71938,"peRate":-76.238621,"turnoverRate":0.042246,"increases":7,"decrements":3,"flats":0,"marketCap":235115634779.5,"floatMarketCap":234393188533},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":2135.9778,"amplitude":0.021997,"preClose":2096.1792,"low":2089.8677,"pbRate":"6.71938","latestPrice":2133.9138,"volume":114156601,"delay":0,"open":2097.0935,"prevYearClose":1682.3505,"prevWeekClose":2024.5422,"prevMonthClose":2060.2607,"prevQuarterClose":1802.0435,"fiveDayClose":2031.6586,"twentyDayClose":2072.2104,"sixtyDayClose":1771.2783,"secType":"PLATE","market":"US","turnoverRate":0.042246,"peRate":-76.238621,"marketCap":235115634779.5,"floatMarketCap":234393188533,"timestamp":1789675199999,"nameCN":"猴痘概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":7,"down":3,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668499884","title":"AETHLON MEDICAL与NORTH IMMUNOLOGY达成合并协议后，股价飙升467%至8.16美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2668499884","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668499884?lang=zh_cn&edition=fundamental","pubTime":"2026-09-17 21:44","pubTimestamp":1789652692,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4568","AEMD","BK4082","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668096118","title":"Aethlon Medical与North Immunology合并后股价飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=2668096118","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668096118?lang=zh_cn&edition=fundamental","pubTime":"2026-09-17 19:31","pubTimestamp":1789644702,"startTime":"0","endTime":"0","summary":"BUZZ-Aethlon Medical与North Immunology合并后股价飙升9月17日-** 医疗设备开发商 Aethlon Medical（AEMD.O）与私营生物技术公司 North Immunology 达成全股票合并协议后，其股价在盘前交易中飙升 430%，至 7.58 美元** 若涨势得以维持，该股开盘价将创下自2026年6月以来的新高** 合并后公司将以“North Imm","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nL4T4590XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","AEMD","BK4583","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118582759","title":"Aethlon Medical宣布与North Immunology达成合并协议，盘前股价飙升87.4%至2.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118582759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118582759?lang=zh_cn&edition=fundamental","pubTime":"2026-09-17 18:36","pubTimestamp":1789641419,"startTime":"0","endTime":"0","summary":"Aethlon Medical Inc股价在盘前交易中暴涨87.4%，报2.68美元。此前，该公司宣布已与North Immunology签署合并协议。这一重磅消息瞬间点燃市场热情，投资者竞相涌入，推动股价大幅攀升。Aethlon Medical的此番动作，标志着其在生物医药领域的战略布局迈出了关键一步。市场分析人士认为，此次合并有望整合双方优势资源，加速创新疗法的研发与商业化进程，前景值得期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4082","BK4568","AEMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121640138","title":"Aethlon Medical：合并前原股东持股约4.75%，North Immunology股东将掌控合并后公司约95.25%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1121640138","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121640138?lang=zh_cn&edition=fundamental","pubTime":"2026-09-17 18:32","pubTimestamp":1789641129,"startTime":"0","endTime":"0","summary":"Aethlon Medical宣布，其与North Immunology的合并交易完成后，原Aethlon股东将持有合并后实体约4.75%的股份，而North Immunology股东则持有剩余约95.25%的股份。这一比例分配反映了双方在交易中的相对估值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4583","AEMD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195928257","title":"Aethlon Medical合并案揭晓：North Immunology原股东预计持有合并实体约95.25%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1195928257","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195928257?lang=zh_cn&edition=fundamental","pubTime":"2026-09-17 18:32","pubTimestamp":1789641128,"startTime":"0","endTime":"0","summary":"Aethlon Medical Inc——在即将完成的合并交易中，North Immunology现有股东预计将持有合并后公司约95.25%的股权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEMD","BK4583","BK4082","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111255872","title":"Aethlon Medical与North Immunology合并，共推新型IL-13×IL-18双特异性抗体治疗特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1111255872","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111255872?lang=zh_cn&edition=fundamental","pubTime":"2026-09-17 18:31","pubTimestamp":1789641070,"startTime":"0","endTime":"0","summary":"Aethlon Medical与North Immunology宣布达成合并协议。此次合并旨在加速推进一款针对特应性皮炎的新型IL-13×IL-18双特异性抗体的临床开发。双方表示，这一战略整合将汇聚两家公司在免疫学与抗体工程领域的专长，有望为特应性皮炎患者带来更具针对性的治疗选择。分析人士指出，特应性皮炎治疗领域竞争日趋激烈，差异化靶点组合或将成为未来药物研发的重要方向。Aethlon Medical与North Immunology的此番联手，或许能为该领域注入新的变量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4583","BK4082","AEMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164691459","title":"吉利德科学扩大六项免许可费自愿授权协议，力推每年一次HIV预防药Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=1164691459","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164691459?lang=zh_cn&edition=fundamental","pubTime":"2026-09-16 20:31","pubTimestamp":1789561872,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，扩大其六项免许可费的自愿授权协议，覆盖其每年仅需注射一次的HIV预防药物Lenacapavir。此举旨在拓宽药物可及性，助力全球抗击艾滋病疫情。通过这一系列协议，吉利德希望加快该长效预防方案在中低收入国家的推广，以应对持续存在的公共卫生挑战。该举措不仅彰显了公司在全球健康公平方面的承诺，也为实现2030年终结艾滋病流行的目标注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0289739699.SGD","GILD","BK4578","BIB","LU0889565916.HKD","IE00B7SZLL34.SGD","BK4550","LU1430594728.SGD","LU1674673428.USD","LU2089984988.USD","LU0823416689.USD","LU2324357040.USD","LU1023059063.AUD","LU1585245621.USD","TMED","LU1037948541.HKD","LU1066053197.SGD","BK4139","MEDI","SG9999015986.USD","IE00B19Z3B42.SGD","LU1934455277.USD","LU0965509101.SGD","LU2087621335.USD","BK4568","IBBQ","IE00BSNM7G36.USD","LU2468319806.SGD","SG9999015978.USD","LU0965509010.AUD","LU1057294990.SGD","LU0109394709.USD","IE0002270589.USD","BK4532","LU0859254822.USD","LU1066051498.USD","BK4585","BMED","LU0861579265.USD","LU2357627491.SGD","SG9999015945.SGD","LU0965509283.SGD","LU0234570918.USD","IE00B19Z3581.USD","BBH","LU0965508806.USD","LU0320765992.SGD","IBB","LU1571399168.USD","IE00BKVL7J92.USD","LU1778281490.HKD","LU2112291526.USD","IE00B3T34201.USD","LU1934455194.USD","BK4566","LU0122379950.USD","LU1674673691.USD","LU1839511570.USD","TBXU","IE00BZ1G4Q59.USD","LU0114720955.EUR","LU1037948897.HKD","SG9999015952.SGD","BK4583","BK4588","LU0058720904.USD","LU1061106388.HKD","LU1934455863.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119302344","title":"Viatris旗下Wakix®（Pitolisant）获日本批准，系发作性睡病及阻塞性睡眠呼吸暂停综合征相关日间过度嗜睡的首创疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1119302344","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119302344?lang=zh_cn&edition=fundamental","pubTime":"2026-09-16 19:00","pubTimestamp":1789556409,"startTime":"0","endTime":"0","summary":"Viatris宣布，其创新药物Wakix®（Pitolisant）已获得日本监管部门的批准。\n这一药物被认定为治疗发作性睡病以及阻塞性睡眠呼吸暂停综合征所伴发的日间过度嗜睡的首创性疗法。\n此次获批标志着Viatris在拓展全球市场、满足患者未竟医疗需求方面迈出了重要一步。\nWakix®的作用机制独特，有别于传统治疗方案，为相关患者群体带来了新的治疗选择。\n日本作为全球重要的药品市场之一，此次批准不仅验证了该药物的临床价值，也为公司未来在亚太地区的进一步布局奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4588","LU2087621335.USD","BK4585","BK4007","VTRS","LU1839511570.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120765496","title":"吉利德科学携手巴西卫生部，共促Lenacapavir本地化生产新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1120765496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120765496?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 23:15","pubTimestamp":1789485331,"startTime":"0","endTime":"0","summary":"吉利德科学公司近日透露，正积极与巴西卫生部探索合作良机，旨在助力该国实现Lenacapavir药物的本土生产愿景。这一举措，无疑为巴西医药产业自主化进程注入了强劲动力。据悉，双方的洽谈聚焦于如何深化协作，以切实推进巴西卫生部既定的战略目标——即构建并强化Lenacapavir的本地制造能力。Lenacapavir，作为一款备受瞩目的长效抗逆转录病毒药物，其本地化生产若能落地，对巴西乃至更广泛地区的HIV防治工作意义深远。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015986.USD","LU1571399168.USD","LU0234570918.USD","BK4566","TBXU","LU0889565916.HKD","LU0058720904.USD","LU0882574055.USD","LU1934455277.USD","LU2087621335.USD","LU1934455194.USD","IBBQ","IE00B7SZLL34.SGD","LU0122379950.USD","GILD","LU0965509010.AUD","BIB","BMED","BK4550","LU1674673428.USD","LU2089984988.USD","LU0320765992.SGD","BK4588","LU0109394709.USD","LU0289739699.SGD","LU2324357040.USD","LU2112291526.USD","BK4139","LU1037948541.HKD","BBH","BK4568","LU0965509283.SGD","LU1839511570.USD","SG9999015952.SGD","LU1066053197.SGD","SG9999015945.SGD","TMED","LU1057294990.SGD","LU1023059063.AUD","IE00B19Z3581.USD","IE00BSNM7G36.USD","BK4578","BK4583","LU1674673691.USD","LU1061106388.HKD","IE00B19Z3B42.SGD","LU1066051498.USD","LU0965509101.SGD","LU2468319806.SGD","LU1934455863.HKD","LU0823416689.USD","LU1778281490.HKD","LU1037948897.HKD","LU1430594728.SGD","IE00B3T34201.USD","SG9999015978.USD","BK4532","IE0002270589.USD","LU0965508806.USD","LU1585245621.USD","BK4585","LU0114720955.EUR","LU0861579265.USD","IBB","LU0859254822.USD","MEDI","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU2357627491.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158863992","title":"吉利德科学：持续探索与泛美卫生组织合作，助力各国准备好并扩大长效艾滋病预防措施的普及","url":"https://stock-news.laohu8.com/highlight/detail?id=1158863992","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158863992?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 23:15","pubTimestamp":1789485330,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）宣布，将继续探索与泛美卫生组织（PAHO）的合作机会，以支持各国做好充分准备，并推动长效艾滋病预防手段的可及性扩展。这一举措旨在强化全球公共卫生应对体系，尤其是针对中低收入国家的需求，通过技术转移、能力建设及供应链优化等途径，加快长效预防方案的落地与规模化应用。双方的合作重点在于应对实施层面的挑战，确保相关资源能够高效、公平地分配至最需要的人群，从而在更大范围内遏制HIV的传播。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU2324357040.USD","SG9999015952.SGD","LU0122379950.USD","IE00B19Z3581.USD","LU1585245621.USD","BIB","SG9999015978.USD","BK4588","BK4566","IBB","LU1057294990.SGD","LU2087621335.USD","LU2357627491.SGD","BK4532","LU1066051498.USD","TMED","LU0965509101.SGD","BK4550","TBXU","BK4568","LU0058720904.USD","BK4585","LU0965509283.SGD","BK4583","IE0002270589.USD","LU0234570918.USD","LU1778281490.HKD","SG9999015986.USD","LU0859254822.USD","LU1037948541.HKD","LU0965508806.USD","LU2468319806.SGD","LU1674673691.USD","LU2112291526.USD","LU0861579265.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","BBH","BK4139","LU0823416689.USD","LU0114720955.EUR","IE00B7SZLL34.SGD","LU1934455194.USD","LU0889565916.HKD","BK4578","BMED","IBBQ","LU1934455277.USD","LU0965509010.AUD","LU1839511570.USD","LU1023059063.AUD","LU1066053197.SGD","SG9999015945.SGD","LU1037948897.HKD","GILD","MEDI","IE00BSNM7G36.USD","LU0882574055.USD","LU1571399168.USD","LU1674673428.USD","LU1061106388.HKD","LU0109394709.USD","LU1430594728.SGD","LU2089984988.USD","LU0320765992.SGD","LU1934455863.HKD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159280995","title":"吉利德科学携手泛美卫生组织，加速拉美及加勒比地区HIV预防药物Lenacapavir的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1159280995","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159280995?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 23:10","pubTimestamp":1789485009,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）日前宣布，与泛美卫生组织（PAHO）达成一项战略合作。此番联手，旨在显著提升一年两针的HIV预防药物Lenacapavir在拉丁美洲及加勒比地区的可及性。双方的合作，将为该区域的高风险人群带来更便捷的预防选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU1023059063.AUD","IE00B7SZLL34.SGD","LU0859254822.USD","LU0965508806.USD","BIB","LU1674673428.USD","IBBQ","IE00B19Z3581.USD","LU1057294990.SGD","LU1037948541.HKD","LU0058720904.USD","LU0823416689.USD","LU1674673691.USD","LU1585245621.USD","LU1778281490.HKD","LU1839511570.USD","LU1934455194.USD","LU1037948897.HKD","LU2112291526.USD","SG9999015945.SGD","LU2324357040.USD","LU0965509283.SGD","LU1934455277.USD","SG9999015952.SGD","SG9999015986.USD","LU1571399168.USD","IE00B19Z3B42.SGD","BMED","LU0861579265.USD","BK4583","LU0965509010.AUD","LU0289739699.SGD","LU0114720955.EUR","IE00B3T34201.USD","LU0882574055.USD","BBH","BK4139","BK4566","BK4585","IE00BSNM7G36.USD","LU1061106388.HKD","IBB","LU1430594728.SGD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","TBXU","GILD","LU2357627491.SGD","SG9999015978.USD","LU0320765992.SGD","LU1066053197.SGD","BK4532","TMED","BK4578","LU1066051498.USD","LU0122379950.USD","LU1934455863.HKD","LU2468319806.SGD","BK4588","LU0965509101.SGD","LU0109394709.USD","LU0889565916.HKD","MEDI","LU2087621335.USD","LU2089984988.USD","BK4568","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153389014","title":"吉利德高管表示，未来几个季度HIV市场增长或将回归2%-3%常态水平","url":"https://stock-news.laohu8.com/highlight/detail?id=1153389014","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153389014?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 23:09","pubTimestamp":1789484948,"startTime":"0","endTime":"0","summary":"吉利德高管在电话会议中透露，该公司预计HIV治疗市场的增长势头将在未来几个季度内逐步趋于稳定，最终回到2%至3%的年增长区间。这一表态正值市场对HIV药物需求持续波动的关键节点。高管指出，当前的增长水平仍高于长期趋势，但随着时间推移，这种偏热的状态将逐渐降温。整个行业的扩张速度，预计将在近期内回落至更为可持续的轨道上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","LU2087621335.USD","IBB","GILD","LU0882574055.USD","LU0058720904.USD","LU0861579265.USD","BK4550","BMED","IE00B19Z3581.USD","LU0122379950.USD","LU0234570918.USD","LU1585245621.USD","TBXU","LU1066053197.SGD","LU1839511570.USD","LU1934455194.USD","BK4566","BBH","LU0965509101.SGD","LU1061106388.HKD","LU0109394709.USD","LU1674673428.USD","IBBQ","IE00BKVL7J92.USD","LU1037948897.HKD","BK4139","LU2112291526.USD","LU2357627491.SGD","IE00BSNM7G36.USD","BK4532","LU0114720955.EUR","LU0289739699.SGD","MEDI","LU1037948541.HKD","BIB","LU1778281490.HKD","SG9999015986.USD","LU1571399168.USD","LU0965509283.SGD","SG9999015978.USD","IE0002270589.USD","BK4583","LU1430594728.SGD","LU1934455277.USD","LU2468319806.SGD","IE00B7SZLL34.SGD","LU0965509010.AUD","BK4585","LU2089984988.USD","LU0965508806.USD","IE00BZ1G4Q59.USD","BK4588","LU0823416689.USD","LU0859254822.USD","LU1066051498.USD","LU1934455863.HKD","LU1023059063.AUD","SG9999015945.SGD","LU1057294990.SGD","LU0889565916.HKD","SG9999015952.SGD","TMED","LU1674673691.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","BK4568","LU0320765992.SGD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131138631","title":"吉利德高管透露：周服HIV预防药物有望2027年第一季度上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1131138631","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131138631?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 23:05","pubTimestamp":1789484737,"startTime":"0","endTime":"0","summary":"吉利德科学高管在电话会议中表示，其每周口服HIV预防药物预计将于2027年第一季度正式推出。这一表态为公司抗艾药物管线注入了新的期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU2324357040.USD","LU0114720955.EUR","MEDI","SG9999015978.USD","LU1430594728.SGD","BIB","IE00B19Z3581.USD","LU1839511570.USD","GILD","LU2089984988.USD","LU1037948541.HKD","LU0965509101.SGD","LU0289739699.SGD","LU2112291526.USD","BK4566","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","IBBQ","LU1037948897.HKD","BK4578","SG9999015986.USD","LU0965508806.USD","LU2468319806.SGD","LU2087621335.USD","LU2357627491.SGD","BK4139","LU1023059063.AUD","LU0320765992.SGD","LU0882574055.USD","LU1934455277.USD","LU0861579265.USD","IE00BSNM7G36.USD","LU1585245621.USD","LU0122379950.USD","LU0234570918.USD","LU1778281490.HKD","BK4568","LU0889565916.HKD","LU0058720904.USD","LU1674673691.USD","BK4550","LU1061106388.HKD","LU1571399168.USD","BMED","LU1066053197.SGD","IE00B3T34201.USD","IE0002270589.USD","BBH","IE00BKVL7J92.USD","LU1934455863.HKD","BK4585","TBXU","TMED","IE00B19Z3B42.SGD","LU0965509283.SGD","LU0109394709.USD","LU0823416689.USD","LU1057294990.SGD","LU0859254822.USD","SG9999015945.SGD","BK4588","LU1674673428.USD","LU1934455194.USD","IBB","BK4532","LU0965509010.AUD","SG9999015952.SGD","LU1066051498.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580494","title":"Leerink基于增长势头改善，给予Viatris“跑赢大盘”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580494","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580494?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 19:48","pubTimestamp":1788954528,"startTime":"0","endTime":"0","summary":"BUZZ-Leerink基于增长势头改善，给予Viatris“跑赢大盘”评级9月9日-** 利林克合伙公司（Leerink Partners）首次覆盖制药公司维亚特里斯（Viatris，VTRS.O），给予“跑赢大盘”评级，目标价为20美元** 该券商预计，在连续三年下滑后，2026年该公司营收和调整后EBITDA将实现增长，其预测值接近公司预期和市场预期的上限** 认为随着维亚特里斯仿制药业务趋","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL4S45110L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","VTRS","BK4583","LU1839511570.USD","BK4588","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136308873","title":"Assembly Biosciences有望获得高达2.8亿美元里程碑付款及美国境外特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1136308873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136308873?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897732,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前披露，其在海外市场具备资格获取最高达2.8亿美元的里程碑款项，外加相应特许权使用费收入。据悉，这家生物科技企业所预期的资金流入将源自美国以外地区。对Assembly Biosciences而言，这笔潜在收入不仅反映其管线资产的外部合作价值，也可能为其后续研发投入提供坚实支撑。市场人士认为，此类非美国市场的收益结构有助于分散地域风险，增强公司财务韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","LU0965509283.SGD","IE00B7SZLL34.SGD","IBB","LU1585245621.USD","IE00B3T34201.USD","MEDI","BMED","LU0234570918.USD","LU1037948897.HKD","LU2089984988.USD","TMED","LU0289739699.SGD","LU1430594728.SGD","LU2087621335.USD","BK4588","LU2468319806.SGD","LU1778281490.HKD","SG9999015952.SGD","LU1037948541.HKD","SG9999015986.USD","ASMB","LU0122379950.USD","BK4583","BK4585","IE00BKVL7J92.USD","BK4532","BK4139","BBH","LU2112291526.USD","BIB","TBXU","LU0823416689.USD","LU1066051498.USD","LU0058720904.USD","IE00BSNM7G36.USD","LU0109394709.USD","LU1934455863.HKD","SG9999015978.USD","IBBQ","LU0965508806.USD","LU2324357040.USD","BK4550","BK4568","LU0965509101.SGD","IE00BZ1G4Q59.USD","SG9999015945.SGD","LU1674673691.USD","BK4578","LU0861579265.USD","IE0002270589.USD","LU1061106388.HKD","IE00B19Z3581.USD","LU0889565916.HKD","LU1066053197.SGD","LU0859254822.USD","LU1934455194.USD","LU2357627491.SGD","LU1023059063.AUD","LU1674673428.USD","LU0114720955.EUR","BK4566","LU0965509010.AUD","LU1934455277.USD","LU0882574055.USD","GILD","LU1571399168.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU1839511570.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154623157","title":"Assembly Biosciences旗下Gs-1179预计2026年底前将推进至生殖器疱疹二期临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1154623157","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154623157?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897731,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前宣布，其研发管线中的候选药物Gs-1179有望在2026年年底之前顺利迈入针对生殖器疱疹的二期临床试验阶段。生殖器疱疹作为一种常见的性传播感染疾病，全球患者群体庞大，对创新疗法的需求十分迫切。Assembly Biosciences正积极加速该药物的研发进程，以期尽早为患者带来新的治疗选择。业内分析人士指出，若Gs-1179能够顺利通过后续试验的严格考验，将可能重塑该适应症的市场格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU2087621335.USD","LU1839511570.USD","BK4578","LU0289739699.SGD","IE00B19Z3B42.SGD","IBB","IE00B3T34201.USD","IE00BKVL7J92.USD","LU0882574055.USD","LU0058720904.USD","BMED","LU1585245621.USD","LU2112291526.USD","TMED","LU0859254822.USD","SG9999015978.USD","LU1066051498.USD","LU0965509010.AUD","LU1934455194.USD","GILD","LU0889565916.HKD","SG9999015986.USD","LU1061106388.HKD","LU0114720955.EUR","LU1934455863.HKD","LU1037948541.HKD","LU0320765992.SGD","BK4566","BK4550","BK4568","LU0861579265.USD","LU1674673691.USD","LU1023059063.AUD","SG9999015945.SGD","LU1057294990.SGD","SG9999015952.SGD","IBBQ","BIB","LU2357627491.SGD","LU1934455277.USD","TBXU","IE00B19Z3581.USD","LU0965509283.SGD","BK4532","LU0965508806.USD","LU1430594728.SGD","IE0002270589.USD","LU0109394709.USD","LU1571399168.USD","IE00B7SZLL34.SGD","LU2089984988.USD","BK4585","LU0234570918.USD","LU1066053197.SGD","IE00BZ1G4Q59.USD","LU1674673428.USD","BK4139","BK4583","ASMB","IE00BSNM7G36.USD","MEDI","LU2468319806.SGD","LU0122379950.USD","LU0823416689.USD","LU2324357040.USD","BK4588","LU1037948897.HKD","LU0965509101.SGD","LU1778281490.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115029168","title":"Assembly Biosciences：吉利德独享HSV HPI项目临床开发与商业化权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1115029168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115029168?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897702,"startTime":"0","endTime":"0","summary":"Assembly Biosciences宣布，吉利德科学已保留其HSV HPI项目的独家临床开发及商业化权利。这一决定标志着双方合作进一步深化，吉利德将全权主导该项目的后续推进与市场布局。对于Assembly Biosciences而言，此举不仅明确了合作伙伴的战略优先级，也为其自身聚焦其他管线资源提供了更大灵活性。业内观察人士指出，HSV HPI项目的独家授权，反映了吉利德在抗病毒治疗领域持续加码的雄心，同时也凸显了该类创新疗法在未被满足的医疗需求中所蕴含的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509283.SGD","BBH","BK4578","LU0114720955.EUR","LU0823416689.USD","IE00B19Z3581.USD","LU0861579265.USD","LU0889565916.HKD","LU1066053197.SGD","LU1430594728.SGD","LU1571399168.USD","SG9999015986.USD","LU0320765992.SGD","BK4583","LU1674673691.USD","LU1061106388.HKD","IE00BZ1G4Q59.USD","LU1934455863.HKD","LU2089984988.USD","LU1023059063.AUD","MEDI","LU0965508806.USD","LU0122379950.USD","ASMB","LU2324357040.USD","LU2357627491.SGD","TMED","LU0109394709.USD","IBB","LU1674673428.USD","LU1037948541.HKD","GILD","BMED","SG9999015952.SGD","IE00B7SZLL34.SGD","LU2468319806.SGD","LU1066051498.USD","IE0002270589.USD","LU0882574055.USD","LU1037948897.HKD","LU0859254822.USD","IBBQ","LU1839511570.USD","BK4568","IE00BSNM7G36.USD","LU1057294990.SGD","LU2112291526.USD","IE00B19Z3B42.SGD","BK4532","LU0965509010.AUD","BK4139","BK4585","BK4588","IE00B3T34201.USD","BIB","LU0058720904.USD","BK4550","LU0289739699.SGD","LU1934455194.USD","LU1934455277.USD","SG9999015945.SGD","BK4566","IE00BKVL7J92.USD","LU0965509101.SGD","LU2087621335.USD","SG9999015978.USD","LU1585245621.USD","TBXU","LU0234570918.USD","LU1778281490.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179230759","title":"Assembly Biosciences行使与吉利德关于HSV解旋酶-引物酶抑制剂项目的美国利润分成选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=1179230759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179230759?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897669,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司已正式行使与吉利德科学就HSV解旋酶-引物酶抑制剂项目达成的美国利润分成选择权。这一战略举措标志着双方合作进入新阶段，有望加速该抗病毒疗法的临床开发与商业化进程。通过行使该选择权，Assembly Biosciences将能够分享该药物在美国市场的未来收益，同时借助吉利德在抗病毒领域的深厚积累与市场渠道，共同推进这一潜在重磅药物的落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","LU0823416689.USD","BBH","LU1066053197.SGD","LU0234570918.USD","LU1571399168.USD","LU1839511570.USD","LU1934455277.USD","LU0965509010.AUD","SG9999015945.SGD","IBB","BK4585","LU1934455863.HKD","IE0002270589.USD","LU1778281490.HKD","LU0889565916.HKD","LU1057294990.SGD","LU1430594728.SGD","LU1061106388.HKD","LU2468319806.SGD","MEDI","LU0114720955.EUR","BK4139","BMED","LU0965509101.SGD","IE00B19Z3581.USD","BK4583","BK4568","LU1066051498.USD","LU1674673428.USD","TBXU","TMED","LU0861579265.USD","LU0965508806.USD","SG9999015952.SGD","LU1585245621.USD","LU0289739699.SGD","IBBQ","LU0859254822.USD","SG9999015978.USD","GILD","IE00BKVL7J92.USD","BK4550","ASMB","LU0058720904.USD","SG9999015986.USD","LU0122379950.USD","BK4588","IE00BSNM7G36.USD","LU1674673691.USD","BK4566","LU0320765992.SGD","IE00B7SZLL34.SGD","LU1037948541.HKD","LU2089984988.USD","LU2324357040.USD","BIB","BK4578","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU0109394709.USD","LU0882574055.USD","LU1934455194.USD","LU2087621335.USD","BK4532","LU2357627491.SGD","LU1037948897.HKD","LU2112291526.USD","IE00BZ1G4Q59.USD","LU0965509283.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374570","title":"吉利德科学(GILD)股票9月8日盘中下跌3.26%：释放什么信号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374570","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374570?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 01:16","pubTimestamp":1788887780,"startTime":"0","endTime":"0","summary":"• 吉利德在经历了长达数月的持续上涨后，因获利回吐而出现回调。\n• 强劲的第二季度营收主要受其旗舰 HIV 和 Trodelvy 产品线的推动。\n• 分析师维持“买入”评级，平均目标价为 157.79 美元。","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156554-market-movers-gild-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","IBB","LU1023059063.AUD","BK4578","LU0859254822.USD","SG9999015978.USD","IE00B19Z3B42.SGD","BK4568","TBXU","LU2112291526.USD","LU0823416689.USD","LU0320765992.SGD","BBH","LU0114720955.EUR","LU1778281490.HKD","IE00BKVL7J92.USD","GILD","LU1430594728.SGD","IE00BZ1G4Q59.USD","BK4532","LU0109394709.USD","IBBQ","LU1674673428.USD","IE00B19Z3581.USD","IE0002270589.USD","LU2087621335.USD","SG9999015952.SGD","LU0289739699.SGD","LU0965508806.USD","LU1037948541.HKD","MEDI","BIB","LU2324357040.USD","BK4585","SG9999015945.SGD","LU0965509101.SGD","SG9999015986.USD","IE00B3T34201.USD","LU0122379950.USD","LU0058720904.USD","LU1934455277.USD","LU1674673691.USD","LU0882574055.USD","LU0861579265.USD","LU1839511570.USD","BK4583","LU1571399168.USD","BMED","TMED","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664804697","title":"第4次更新-鉴于市场供应存在担忧，美国食品药品监督管理局正与制造商合作，以增加雌激素贴片的供应量","url":"https://stock-news.laohu8.com/highlight/detail?id=2664804697","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664804697?lang=zh_cn&edition=fundamental","pubTime":"2026-09-04 05:02","pubTimestamp":1788469322,"startTime":"0","endTime":"0","summary":"第4次更新-鉴于市场供应存在担忧，美国食品药品监督管理局正与制造商合作，以增加雌激素贴片的供应量在第10段中补充了拜耳的回应Sriparna Roy路透9月3日-美国卫生监管机构周四表示，在接到患者反映难以及时获得该药物的报告后，该机构正与全部六家制造商合作，以增加用于治疗更年期症状的雌二醇透皮贴片的供应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL4S44V1QC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","BK4583","LU1839511570.USD","VTRS","BK4588","AMRX","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}